enGene Therapeutics Inc.
engene.comWhat Do They Do?
Develops non-viral genetic medicines, including a bladder-instilled therapy for bladder cancer, for patients with bladder cancer and other serious diseases.
10-K for FY2025, filed Dec 22, 2025
Sources
How Are They Changing?
Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Jul 31, 2026
- Net income
-
Sources
10-Q for Q3 FY2026, filed Sep 8, 2026
−$32.5MView ↗
- ▲ +12% (Loss)
- vs −$29M in Q3 FY2025
-
Jul 16, 2026
Michael Heffernan became chairman after Richard Glickman resigned
Sources
8-K, filed Jul 16, 2026
On July 15, 2026, Dr. Richard Glickman resigned as a director and chairman of the Board of Directors (the “Board”) of enGene Therapeutics…View ↗
-
Jun 15, 2026
enGene cut its workforce by about half and halted enrollment in three trial cohorts
It also planned to departures for its CFO and other executives while focusing resources on the pivotal and surfactant cohorts and BLA preparation.
Sources
8-K, filed Jun 15, 2026
On June 15, 2026, the Company announced the implementation of a plan to reduce its workforce by approximately 50% to streamline operations…View ↗
Loading...
Comments
